טוען...
CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis
BACKGROUND AND AIMS: Alemtuzumab is a humanized monoclonal antibody that depletes CD52-bearing B and T lymphocytes. Clinical trials defined that systemic administration of alemtuzumab reduces disease severity in the relapsing–remitting phase of multiple sclerosis (MS). However, its efficacy in progr...
שמור ב:
| הוצא לאור ב: | Ther Adv Chronic Dis |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7443992/ https://ncbi.nlm.nih.gov/pubmed/32913622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622320947378 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|